CYP19A1 and breast cancer: For postmenopausal women with breast cancer, the 25-year cumulative risk of contralateral breast cancer was reduced by 6–10% for the 10-year aromatase inhibitors therapy (vs. no adjuvant therapy) (Table 3 and Fig. 4).